ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With One Novel Hormonal Agent First Line and Non-progressive Disease After Second Line Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2017 Status changed from not yet recruiting to recruiting.
- 18 Oct 2016 New trial record